Are Live Vaccines Safe in 22q11.2 Deletion Syndrome?
At a Glance
Most children with 22q11.2 deletion syndrome can safely receive standard childhood vaccines. However, because the syndrome can affect thymus development and T-cell counts, a pediatric immunologist must evaluate the child's immune system before they receive any live vaccines like MMR or rotavirus.
In this answer
3 sections
Most children with 22q11.2 deletion syndrome can safely receive their normal childhood vaccines, including live vaccines [1][2]. However, because this syndrome can affect how the immune system develops, your child must have their immune system evaluated by a pediatric immunologist before receiving any live vaccines [1]. For the majority of children with mild to moderate immune differences, these vaccines are well-tolerated and provide crucial protection [1][2].
Inactive vs. Live Vaccines
Childhood vaccines come in two main types, and the distinction is very important for children with 22q11.2 deletion syndrome:
- Inactive vaccines (such as DTaP, Injected Polio (IPV), Hib, Hepatitis B, and the injected flu shot) use a dead version of a germ or just a piece of it. These cannot cause an infection. They are safe for children with 22q11.2 deletion syndrome and should be given according to the standard childhood schedule [3].
- Live-attenuated vaccines (such as MMR, Varicella/Chickenpox, Rotavirus, and the nasal spray flu vaccine) use a weakened, living version of a virus. In a healthy immune system, this weakened virus safely teaches the body how to fight the disease. However, if a child has a severe immune deficiency, their body may struggle to control even the weakened virus, potentially leading to a serious infection [4]. Note that the Oral Polio Vaccine (OPV) used in some countries outside the U.S. is also a live vaccine, whereas the injected version is inactive.
The Role of the Thymus and T-Cells
Many children with 22q11.2 deletion syndrome are born with an underdeveloped thymus gland—a small organ in the upper chest [3][5]. The thymus acts as a training center for T-cells, which are specialized white blood cells that fight off viral infections [6].
The severity of immune system differences is highly variable in 22q11.2 deletion syndrome [3][7]. Some children have perfectly normal immune systems, some have mild to moderate T-cell lymphopenia (lower than normal T-cell counts), and a very small percentage have severe T-cell deficiency [8][3].
Because of this variability, doctors cannot assume your child’s immune status based on their other symptoms [3][9]. A pediatric immunologist needs to run specific blood tests to check your child’s T-cell counts and function [9][10]. If these tests show your child’s T-cells are functioning adequately—even if the absolute numbers are slightly lower than average—live vaccines can typically be given safely [1][11]. Because immune function can sometimes change over time or during severe illness, keeping an open line of communication with your immunologist for future vaccine catch-ups is always encouraged.
Early Infant Vaccination: The Rotavirus Vaccine
The rotavirus vaccine requires special attention because it is a live vaccine given very early in life, typically at 2 months of age. This is often before a baby has had a comprehensive immune evaluation [1].
Current guidelines strongly recommend that infants with 22q11.2 deletion syndrome have their immune status checked to rule out severe T-cell deficiency before getting the rotavirus vaccine [1][2]. If your baby’s newborn screen for severe combined immunodeficiency (often called the TREC newborn screen) was normal, this is a very reassuring sign that their T-cells are functioning at a baseline level [4]. Even so, you should confirm with your child’s immunologist before proceeding.
What if you cannot see an immunologist by month 2?
If you cannot get an immunology appointment before your baby’s 2-month checkup, it is safer to delay the rotavirus vaccine until clearance is obtained rather than skip the evaluation entirely. The other major live vaccines (MMR and Varicella) are not typically given until around 12 months of age, giving you plenty of time to get the necessary bloodwork done.
A Note on Siblings
Parents often wonder if healthy siblings can safely receive live vaccines without putting the baby at risk. In most cases, it is safe for household contacts to receive their standard vaccines, but you should always discuss this with your child’s immunologist, as certain live vaccines (like the oral rotavirus vaccine) can shed in the stool and require extra hand-washing precautions.
Common questions in this guide
Can babies with 22q11.2 deletion syndrome get normal childhood vaccines?
What is the difference between live and inactive vaccines?
Should my baby get the rotavirus vaccine if they have 22q11.2 deletion syndrome?
Why does 22q11.2 deletion syndrome affect the immune system?
Is it safe for siblings to get live vaccines if my baby has 22q11.2 deletion syndrome?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Can you confirm whether my baby's TREC newborn screen results for severe combined immunodeficiency (SCID) were normal?
- 2.Has my baby had their specific T-cell counts (CD3, CD4, CD8) and lymphocyte proliferation tests drawn yet, and what were the results?
- 3.Before we proceed with shots today, can you verify exactly which of the vaccines are inactive and which are live-attenuated?
- 4.If we need to delay the rotavirus vaccine until we see the immunologist, what is the latest window we can safely start the series?
- 5.Are there any special precautions we need to take when older siblings receive their live vaccines, like the rotavirus or nasal flu spray?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
[Live Vaccine in Children with DiGeorge/22q11.2 Deletion Syndrome].
Miranda M, Martins AT, Carvalho S, et al.
Acta medica portuguesa 2019; (32(7-8)):514-519 doi:10.20344/amp.9802.
PMID: 31445531 - 2
Evaluation of rotavirus vaccine administration among a 22q11.2DS patient population.
McGregor S, Boroditsky M, Blanchard-Rohner G, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022; (18(1)):50 doi:10.1186/s13223-022-00693-z.
PMID: 35690869 - 3
Immune and Genetic Features of the Chromosome 22q11.2 Deletion (DiGeorge Syndrome).
Kuo CY, Signer R, Saitta SC
Current allergy and asthma reports 2018; (18(12)):75 doi:10.1007/s11882-018-0823-5.
PMID: 30377837 - 4
Persistent infection with a rotavirus vaccine strain in a child suffering from Severe Combined Immunodeficiency in Argentina.
Palau MJ, Vescina CM, Regairaz L, et al.
Revista Argentina de microbiologia 2021; (53(3)):216-219 doi:10.1016/j.ram.2020.10.002.
PMID: 33526290 - 5
Clinical Phenotype, Immunological Abnormalities, and Genomic Findings in Patients with DiGeorge Spectrum Phenotype without 22q11.2 Deletion.
Cirillo E, Prencipe MR, Giardino G, et al.
The journal of allergy and clinical immunology. In practice 2020; (8(9)):3112-3120 doi:10.1016/j.jaip.2020.06.051.
PMID: 32668295 - 6
Prevalence of immunological aberrations and 22q11.2 deletion in children with conotruncal anomalies: A cross-sectional study.
Das S, Baranwal AK, Rawat A, et al.
Annals of pediatric cardiology 2024; (17(5)):339-346 doi:10.4103/apc.apc_168_24.
PMID: 39830497 - 7
Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome.
Crowley B, Ruffner M, McDonald McGinn DM, Sullivan KE
American journal of medical genetics. Part A 2018; (176(10)):2082-2086 doi:10.1002/ajmg.a.38597.
PMID: 29341423 - 8
Clinical and Immunological Features of a Large DiGeorge Syndrome Cohort.
Süleyman M, Cagdas D, Kiper PÖŞ, et al.
Journal of clinical immunology 2025; (45(1)):103.
PMID: 40461840 - 9
Risk factors of clinical dysimmune manifestations in a cohort of 86 children with 22q11.2 deletion syndrome: A retrospective study in France.
Mahé P, Nagot N, Portales P, et al.
American journal of medical genetics. Part A 2019; (179(11)):2207-2213 doi:10.1002/ajmg.a.61336.
PMID: 31471951 - 10
Clinical characteristics and immunological status of patients with 22q11.2 deletion syndrome in Northern Thailand.
Ua-Areechit T, Varnado P, Tengsujaritkul M, et al.
Asian Pacific journal of allergy and immunology 2023; (41(1)):89-95 doi:10.12932/AP-241019-0671.
PMID: 32416666 - 11
Characterization of Infants with Idiopathic Transient and Persistent T Cell Lymphopenia Identified by Newborn Screening-a Single-Center Experience in New York State.
Jongco AM, Sporter R, Hon E, et al.
Journal of clinical immunology 2021; (41(3)):610-620 doi:10.1007/s10875-020-00957-6.
PMID: 33411154
This page provides educational information about vaccine safety for children with 22q11.2 deletion syndrome. Always consult your pediatric immunologist before administering live vaccines to your child.
Get notified when new evidence is published on 22q11.2 deletion syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.